Quantitative Investment Management LLC Buys New Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• Quantitative Investment Management LLC has acquired a new stake in Zimmer Biomet Holdings, Inc. valued at approximately $2.3 million, purchasing 20,480 shares in the first quarter.
• Several institutional investors, including Brighton Jones LLC and Jump Financial LLC, have increased their stakes in Zimmer Biomet, resulting in 88.89% of the stock being owned by hedge funds and other institutions.
• Research analysts have mixed ratings on Zimmer Biomet, with an average price target of $111.44, indicating both bullish and bearish sentiments among various firms.

Quantitative Investment Management LLC bought a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm bought 20,480 shares of the medical equipment provider's stock, valued at approximately $2,317,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in ZBH. Garde Capital Inc. acquired a new position in Zimmer Biomet during the first quarter valued at approximately $29,000. Menard Financial Group LLC bought a new stake in shares of Zimmer Biomet during the 4th quarter worth $30,000. Washington Trust Advisors Inc. acquired a new stake in Zimmer Biomet in the first quarter valued at about $30,000. Columbia River Financial Group LLC bought a new position in Zimmer Biomet in the first quarter valued at about $30,000. Finally, Accent Capital Management LLC bought a new position in Zimmer Biomet in the first quarter valued at about $35,000. Institutional investors own 88.89% of the company's stock.

Zimmer Biomet Trading Down 1.6%

Shares of NYSE:ZBH traded down $1.74 during trading on Thursday, reaching $105.05. The stock had a trading volume of 1,092,859 shares, compared to its average volume of 2,037,245. Zimmer Biomet Holdings, Inc. has a 52 week low of $89.22 and a 52 week high of $116.71. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.96 and a current ratio of 1.87. The firm's fifty day moving average is $96.50 and its 200 day moving average is $99.39. The stock has a market cap of $20.81 billion, a price-to-earnings ratio of 25.56, a P/E/G ratio of 2.12 and a beta of 0.68.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping analysts' consensus estimates of $1.98 by $0.09. The business had revenue of $2.08 billion during the quarter, compared to the consensus estimate of $2.06 billion. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. Zimmer Biomet's quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter last year, the firm earned $2.01 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.9%. Zimmer Biomet's dividend payout ratio (DPR) is 23.36%.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on ZBH. Raymond James Financial raised their price target on shares of Zimmer Biomet from $104.00 to $113.00 and gave the company an "outperform" rating in a research note on Friday, August 8th. Truist Financial set a $101.00 target price on shares of Zimmer Biomet in a research report on Tuesday, May 6th. UBS Group boosted their target price on shares of Zimmer Biomet from $91.00 to $96.00 and gave the stock a "sell" rating in a research note on Friday, August 8th. Evercore ISI cut their price objective on Zimmer Biomet from $102.00 to $96.00 and set an "in-line" rating on the stock in a report on Tuesday, July 8th. Finally, Stifel Nicolaus set a $115.00 target price on Zimmer Biomet and gave the stock a "buy" rating in a report on Tuesday, May 6th. Nine analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $111.44.

Insider Buying and Selling at Zimmer Biomet

In related news, insider Sang Yi sold 1,000 shares of the business's stock in a transaction on Wednesday, June 11th. The shares were sold at an average price of $95.00, for a total transaction of $95,000.00. Following the transaction, the insider owned 20,424 shares in the company, valued at $1,940,280. The trade was a 4.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.39% of the stock is owned by corporate insiders.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.